Multiomics profiling Identifies MCMBP as a prognostic biomarker and a potential immune-related target in pancreatic ductal adenocarcinoma via the JAK–STAT3 pathway
Overexpression of MCMBP may serve as a prognostic biomarker and p-otential therapeutic target in PAAD. It drives PAAD progression by activating the JAK-STAT3 pathway to upregulate PD-L1.
Authors
- Bixuan Li
- Lei Zhang (ORCID: https://orcid.org/0000-0003-2343-084X)
- Yang Wang (ORCID: https://orcid.org/0000-0002-0535-2414)
- Xi Ma (ORCID: https://orcid.org/0000-0003-1976-7351)
- Xinghai Zhang
- Wenping Xu (ORCID: https://orcid.org/0000-0002-2062-4641)
- Hao Yuan (ORCID: https://orcid.org/0000-0003-3269-3326)
- Fangxuan Li (ORCID: https://orcid.org/0000-0002-1188-6922)
- Yuzhuo Li
- Yujia Chen (ORCID: https://orcid.org/0009-0000-7779-5559)
- Jiaqi Ma
- Yixin Wang (ORCID: https://orcid.org/0009-0006-7320-1657)
Institutions
- Xi'an Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1621927
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00